Skip to main content
SpringerLink
Log in

COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To evaluate the main characteristics of case reports of arterial hypertension (AH) related to COX-2 inhibitor (coxib) use in real-life practice.

Methods

This study was based on spontaneous reports of adverse drug reactions (ADRs) submitted to the French Pharmacovigilance system. Associations between AH and the different groups of those using non-steroidal anti-inflammatory drugs (NSAIDs: rofecoxib, celecoxib and non-selective NSAIDs) were compared using calculation of the odds ratio (OR) with 95% confidence intervals (CIs).

Results

In France, between 1 April 2000 and 30 November 2003, 34 AH cases related to coxibs were reported. Case reports include predominantly patients older than 65 years, with a previous story of essential AH. Most AH (60%) occurred during the first 15 days of treatment. The AH was reported significantly more frequently for rofecoxib than celecoxib. The OR for development of AH with rofecoxib versus celecoxib was 3.3 (1.6–6.9). The AH was also reported more frequently with coxib (2.8%) than with non-selective NSAID (0.5%) use, OR = 5.9 (3.8–9.0).

Conclusion

This study shows that coxibs are associated with a risk of AH in real-life practice. More spontaneous reports of AH to the French Pharmacovigilance system concern rofecoxib than celecoxib (and coxibs than non-selective NSAIDs). This ADR is of special epidemiological importance due to both the risks of AH and the large use of coxibs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153:477–484

    Article  PubMed  Google Scholar 

  2. Jonhson AG, Nguyen TV, Day RO (1994) Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 121:289–300

    PubMed  Google Scholar 

  3. Frishman W (2002) Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 89(Suppl):18D–25D

    Article  PubMed  Google Scholar 

  4. Amstrong E, Malone D (2003) The impact of non-steroidal anti-inflammatory drugs on blood pressure, with emphasis on newer agents. Clin Ther 25:1–18

    Article  PubMed  Google Scholar 

  5. Edwards I, Aronson J (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1260

    Article  PubMed  Google Scholar 

  6. Bégaud B, Evreux JC, Jouglard J, Lagier G (1985) Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie 40:111–118

    PubMed  Google Scholar 

  7. Whelton A, White W, Bello A, Puma J, Fort J, *the SUCCESS-VII Investigators (2002) Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90:959–963

    Article  PubMed  Google Scholar 

  8. Zhao S, Reynolds M, Lefkowitz J, Whelthon A, Arellano F (2001) A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World health Organisation/Uppsala Monitoring Centre Safety Database. Clin Ther 23:1478–1491

    Article  PubMed  Google Scholar 

  9. Solomon D, Schneeweiss S, Levin R, Avorn J (2004) Relationship between COX-2 specific inhibitors and hypertension. Hypertension 44:140–145

    Article  PubMed  Google Scholar 

  10. Wolfe F, Zhao S, Reynolds M, Petitt D (2004) Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 31:1143–11151

    PubMed  Google Scholar 

  11. Brinker A, Goldkind L, Bonnel R, Beitz J (2004) Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Drugs Aging 21:479–484

    PubMed  Google Scholar 

  12. Mandani M, Juurlink D, Lee D, Rochon P, Koop A, Naglie G, Austin P (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751–1756

    Article  PubMed  Google Scholar 

  13. Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA (2004) High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 13:339–343

    Article  PubMed  Google Scholar 

  14. Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastro-intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis; VIGOR Study Group. N Engl J Med 343:1520–1528

    Article  PubMed  Google Scholar 

  15. Silverstein FE, Faich G, Golstein JL et al (2000) for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the class study: a randomized controlled trial. JAMA 284:1247–1255

    PubMed  Google Scholar 

  16. Whelton A, Singh G, White W et al (2001) Celecoxib does not increase the risk of cardiac failure, edema, or hypertension compared to NSAIDs: results from SUCCESS 1, a double blind, randomized trial in 13 274 OA patients. In: Program and abstracts of the American College of Rheumatology 65th Annual Scientific Meeting; November 10–15, San Francisco, CA, Abstract

  17. Riendeau D, Percival MD, Brideau C et al (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558–566

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Pharmacologie Clinique, Faculté de Médecine de Toulouse, Unité de Pharmacoépidémiologie UA 3696, IFR INSERM 126, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmaco épidémiologie et d’Informations sur le Médicament, 37 Allées Jules Guesde, 31073, Toulouse Cedex 7, France

    G. Durrieu, P. Olivier & J. L. Montastruc

Authors
  1. G. Durrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Olivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. L. Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The French networks of Pharmacovigilance centers

Corresponding author

Correspondence to G. Durrieu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durrieu, G., Olivier, P., Montastruc, J.L. et al. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database. Eur J Clin Pharmacol 61, 611–614 (2005). https://doi.org/10.1007/s00228-005-0964-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0964-z

Keywords

Search

Navigation